RM-1 Syngeneic Model Service for Prostate Cancer

The RM-1 syngeneic model is the Ras-and-Myc-transformed, immunocompetent workhorse for aggressive late-stage prostate cancer, engrafting a low-MHC-I murine prostate carcinoma into C57BL/6 hosts where documented checkpoint refractoriness and quantified radiation responsiveness make it the reference substrate for cold-to-hot combination strategies. Alfa Cytology delivers this benchmark model as a complete preclinical service — authenticated cell banking with stable androgen-receptor characterization, subcutaneous or orthotopic implantation, SARRP-calibrated radiation and checkpoint combination arms, and full metastasis-aware histopathology — giving sponsors the most quantified immunotherapy-refractory prostate system available.

Overview of RM-1 Syngeneic Model for Prostate Cancer

RM-1 has an origin story that reads like a history of engineered prostate cancer modeling: cells were isolated from the urogenital sinus — the embryonic anlage of the prostate — of 17-day fetal C57BL/6 mice and transformed with the Zip-ras/myc9 retrovirus, which installs v-Ha-Ras and v-Myc oncogenes in a single construct; the resulting line forms poorly differentiated prostate carcinomas with high frequency in syngeneic hosts and retains the luminal epithelial marker cytokeratin-18. Its androgen biology is nuanced and instructive: testosterone produces a roughly two-fold mitogenic response in serum-free culture, androgen-receptor numbers and binding kinetics remain stable across passages, yet in vivo growth is androgen-independent — a profile that places RM-1 naturally in the late-stage, hormone-refractory setting where human disease becomes lethal. Immunologically the line is defined by what it lacks: low MHC class I expression renders it nearly invisible to T cells, irradiated whole-cell vaccines fail to clear established tumors in male hosts — attributed to prostate-antigen tolerance — and the model is consequently classified among the aggressive, nonimmunogenic prostate carcinomas.

Fig 1. In vivo efficacy of PKMYT1 inhibitor RP-6306 in immunocompetent C57BL/6 versus nude mice bearing RM-1 or TRAMP-C2 tumors, with bioluminescence imaging of lung metastases, showing that PKMYT1 inhibition suppresses tumor growth in immune-intact hosts and synergizes with anti-PD-L1 therapy. (Gao, Lin, et al., 2026)

That immunological coldness, paradoxically, is what has made RM-1 the reference system for combination immunotherapy in prostate cancer. A comprehensive model-characterization effort quantified its checkpoints response precisely: single-agent anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 produced minimal activity with no regressions, while tumor-infiltrating-lymphocyte profiling read the tumor as "cool" with a clear cold-to-hot opportunity. The same study mapped its radiation response on a small-animal radiation research platform with unusual granularity — 20 Gy yielding 100% putative responders, 10 Gy 78%, and 5 Gy 89% — and identified 5 Gy plus anti-mPD-1 as an optimized combination backbone. Orthotopically, RM-1 is ferociously metastatic: prostatic implantation produces metastatic activity in over 80% of animals by days 16–17, with the pelvic and retroperitoneal lymph nodes — not the lung — as the predominant sites, alongside invasion of surrounding tissues and bloody ascites in advanced disease; intraosseous injection additionally supports osteolytic-osteoblastic bone-stroma questions through documented RANKL engagement. The vaccine literature carries a finding few models can offer: GM-CSF surface-modified RM-1 cells, engineered by rapid streptavidin–biotin cytokine display, protected female hosts while males — prostate-antigen tolerant — remained susceptible, an antigen-tolerance lesson that still shapes vaccine-arm design, and ibrutinib has been shown to convert the cold RM-1 microenvironment toward PD-1 responsiveness. For sponsors pursuing radiation-immunotherapy combinations, cold-to-hot strategies, or lymph-node-dominant metastatic disease, RM-1 offers quantified benchmarks few prostate models can match.

Cell Line Information: RM-1 Syngeneic Model

RM-1 (Cellosaurus CVCL_B459; Cytion 305168) is the v-Ha-Ras/v-Myc-transformed murine prostate carcinoma line derived from 17-day fetal C57BL/6 urogenital sinus cells, distributed through academic repositories and international cell banks. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the RM-1 syngeneic model places the most quantified immunotherapy-refractory prostate system under one accountable team: authenticated, low-passage RM-1 banks are maintained with stable androgen-receptor characterization and CK18 identity verification, syngeneic C57BL/6 hosts are sourced and acclimated, tumors are established subcutaneously for rapid efficacy screens or orthotopically for lymph-node-dominant metastatic studies, and treatment arms — checkpoint blockade expected to confirm refractoriness, SARRP-calibrated radiation at the benchmark 5 Gy backbone, cold-to-hot combinations, or whole-cell vaccine formats — run through scheduled caliper monitoring to terminal metastasis-aware histopathology, all under IACUC-compliant conditions and returned as an audit-ready data package.

Workflow of RM-1 Syngeneic Model Construction

RM-1 studies divide into rapid flank efficacy screening and the aggressive orthotopic format with its days 16–17 metastatic window, both resting on the line's documented checkpoint-refractory baseline. A standard program proceeds as follows.

1. Cell preparation and quality control: RM-1 cells are expanded at low passage, confirmed mycoplasma-free, and identity verified (CK18 expression with stable androgen-receptor numbers and binding kinetics); suspensions are prepared fresh at defined inocula.
2. Host selection and acclimation: Male C57BL/6 mice, typically 4–6 weeks of age (16–20 g), are quarantined and acclimated in a specific-pathogen-free barrier facility.
3. Implantation: subcutaneous route. Cells in 0.1 mL sterile PBS are injected into the flank; the site is compressed briefly on needle withdrawal, and reproducible tumors establish for chemotherapy, targeted-drug, and immunotherapy screening.
4. Implantation: orthotopic route. Under isoflurane anesthesia, a midline laparotomy exposes the prostate and the cell suspension is injected into the prostatic parenchyma; the abdomen is closed and advanced disease is monitored for the documented days 16–17 metastatic window with pelvic and retroperitoneal lymph-node spread.
5. Randomization and checkpoint benchmarking: Mice are randomized by tumor volume into arms; anti-mPD-1, anti-mPD-L1, or anti-mCTLA-4 benchmark arms run in parallel to confirm the documented refractory baseline before combination strategies are judged.
6. Radiation and combination treatment. Test articles are dosed per protocol: focal-beam radiation on the small-animal radiation research platform (with the documented 5 Gy backbone), cold-to-hot agents such as BTK-pathway modulators, vaccine formats, or their combinations — with body weight recorded.
7. Longitudinal monitoring: Flank tumors are measured by caliper on the protocol cadence; orthotopic cohorts are monitored for weight loss, abdominal distension, and signs of bloody ascites, with humane endpoints predefined against the aggressive disease course.
8. Endpoint analysis and reporting: At termination, primary tumors, pelvic and retroperitoneal lymph nodes, lungs, and bone are resected; tissues undergo H&E with prostate histology, immunohistochemistry (CD8, CD4, FoxP3, F4/80, CD31, PD-L1, CK18 panels), metastatic nodule enumeration per organ, and tumor-infiltrating-lymphocyte flow cytometry for cold-to-hot assessment, with all data consolidated into the final report.

Fig 2. RM-1 Syngeneic Model construction workflow.

Case Study-RM-1 Syngeneic Model

Alfa Cytology has applied the RM-1 syngeneic platform to preclinical programs spanning radiation-immunotherapy combinations, checkpoint blockade in refractory disease, cold-to-hot microenvironment strategies, orthotopic lymph-node metastasis evaluation, and bone-stroma interaction studies in prostate cancer. In these engagements, caliper readouts tracked flank tumor kinetics, orthotopic cohorts were followed through the documented metastatic window, checkpoint benchmark arms confirmed the refractory baseline, and terminal metastasis-aware histopathology with immune-marker panels completed the pharmacological and immunological assessment. Study parameters — implantation format, radiation dosing, treatment arms, and endpoint panels — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

RM-1 rewards teams that respect its arithmetic: the 100/78/89% radiation-responder tiers, the no-regression checkpoint baseline, the 16–17-day metastatic clock, and the antigen-tolerance lesson behind its vaccine failures. Alfa Cytology fields these quantified capabilities in-house, making the RM-1 syngeneic model a dependable backbone for your prostate cancer program.

• Zip-ras/myc9 transformation pedigree, with CK18 luminal identity and stable androgen-receptor kinetics.
• Quantified checkpoint-refractory baseline, with anti-mPD-1/PD-L1/CTLA-4 benchmarks run natively.
• SARRP-calibrated radiation benchmarks, deploying the documented 20/10/5 Gy responder tiers.
• Optimized 5 Gy + anti-PD-1 combination backbone, validated in the published characterization.
• Orthotopic metastatic geometry, with the documented days 16–17 pelvic and retroperitoneal spread.
• Antigen-tolerance literacy, informed by the sex-difference vaccine findings and ibrutinib cold-to-hot precedent.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your prostate cancer program targets immunotherapy-refractory disease, radiation combinations, or lymph-node-dominant metastasis, contact us today to discuss RM-1 study design, benchmark arms, and endpoint strategy with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.